Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children
- PMID: 15551207
- DOI: 10.1086/425981
Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children
Abstract
We evaluated a combination respiratory syncytial virus (RSV) and parainfluenza 3 virus (PIV3) live, attenuated intranasal vaccine for safety, viral replication, and immunogenicity in doubly seronegative children 6-18 months old. RSV cpts-248/404 and PIV3-cp45 vaccines were combined in a dose of 10(5) plaque-forming units of each per 0.5-mL dose and compared with monovalent vaccines or placebo. The virus shedding pattern of RSV was not different between monovalent RSV cpts-248/404 vaccine and combination vaccine. Modest reductions in the shedding of PIV3-cp45 vaccine virus were found after the administration of RSV cpts-248/404 and PIV3-cp45 vaccine, relative to monovalent PIV3 vaccine; 16 (76%) of 21 children given combination vaccine shed PIV3-cp45 versus 11 (92%) of 12 of those given monovalent PIV3 vaccine. Both vaccines were immunogenic, and antibody responses were similar between the monovalent groups and the combination group. Combined RSV/PV3 vaccine is feasible for simultaneous administration, and further studies are warranted.
Similar articles
-
Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.Pediatr Infect Dis J. 2009 Jul;28(7):655-8. doi: 10.1097/INF.0b013e318199c3b1. Pediatr Infect Dis J. 2009. PMID: 19483659 Clinical Trial.
-
Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.Vaccine. 2008 Nov 25;26(50):6373-82. doi: 10.1016/j.vaccine.2008.09.018. Epub 2008 Sep 24. Vaccine. 2008. PMID: 18822334 Clinical Trial.
-
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.J Infect Dis. 2005 Apr 1;191(7):1093-104. doi: 10.1086/427813. Epub 2005 Mar 1. J Infect Dis. 2005. PMID: 15747245 Clinical Trial.
-
Current status of vaccines for parainfluenza virus infections.Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S123-5. doi: 10.1097/INF.0b013e318168b76f. Pediatr Infect Dis J. 2008. PMID: 18820572 Review.
-
PIV-3 vaccine National Institutes of Health/Aviron.Curr Opin Investig Drugs. 2001 Jul;2(7):890-2. Curr Opin Investig Drugs. 2001. PMID: 11757785 Review.
Cited by
-
Croup.Lancet. 2008 Jan 26;371(9609):329-39. doi: 10.1016/S0140-6736(08)60170-1. Lancet. 2008. PMID: 18295000 Free PMC article. Review.
-
The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children.Pediatr Infect Dis J. 2011 Oct;30(10):e186-91. doi: 10.1097/INF.0b013e31822ea24f. Pediatr Infect Dis J. 2011. PMID: 21829138 Free PMC article. Clinical Trial.
-
Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics.J Virol. 2012 Oct;86(19):10792-804. doi: 10.1128/JVI.01227-12. Epub 2012 Jul 25. J Virol. 2012. PMID: 22837193 Free PMC article.
-
Pulmonary eosinophils and their role in immunopathologic responses to formalin-inactivated pneumonia virus of mice.J Immunol. 2009 Jul 1;183(1):604-12. doi: 10.4049/jimmunol.0802270. J Immunol. 2009. PMID: 19542471 Free PMC article.
-
Vaccines for the common cold.Cochrane Database Syst Rev. 2017 May 18;5(5):CD002190. doi: 10.1002/14651858.CD002190.pub5. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2022 Dec 14;12:CD002190. doi: 10.1002/14651858.CD002190.pub6 PMID: 28516442 Free PMC article. Updated. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
